De novo discovery of antibody drugs – great promise demands scrutiny

References

• Desjarlais JR, Lazar GA. Negative design for improved therapeutic proteins. Trends Biotechnol. 2003;21:425–27. doi:10.1016/S0167-7799(03)00205-1.
   PubMed Web of Science ®Google Scholar
• Caravella JA, Wang D, Glaser SM, Lugovskoy A. Structure-Guided Design of Antibodies. Curr Comput Aided Drug Des. 2010;6:128-138.
   Web of Science ®Google Scholar
• Harms BD, Kearns JD, Iadevaia S, Lugovskoy AA. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods. 2014;65:95–104. doi:10.1016/j.ymeth.2013.07.017.
   PubMed Web of Science ®Google Scholar
• van Steeg TJ, Bergmann KR, Dimasi N, Sachsenmeier KF, Agoram B. The application of mathematical modelling to the design of bispecific monoclonal antibodies. MAbs. 2016;8:585–92. doi:10.1080/19420862.2016.1141160.
   PubMed Web of Science ®Google Scholar
• Fenn J, Raskino M. Mastering the hype cycle: how to choose the right innovation at the right time. Boston (Mass.): Harvard Business Press; 2008.
   Google Scholar
• Vásquez M, Krauland E, Walker L, Wittrup D, Gerngross T Connecting the sequence dots: shedding light on the genesis of antibodies reported to be designed in silico. MAbs. 2019.
   PubMed Web of Science ®Google Scholar
• Tharakaraman K, Subramanian V, Viswanathan K, Sloan S, Yen HL, Barnard DL, Leung YHC, Szretter KJ, Koch TJ, Delaney JC, et al. A broadly neutralizing human monoclonal antibody is effective against H7N9. Proc Natl Acad Sci U S A. 2015;112:10890–95. doi:10.1073/pnas.1502374112.
   PubMed Web of Science ®Google Scholar
• Tharakaraman K, Watanabe S, Chan KR, Huan J, Subramanian V, Chionh YH, Raguram A, Quinlan D, McBee M, Ong EZ, et al. Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope. Cell Host Microbe. 2018;23:618–27 e6. doi:10.1016/j.chom.2018.04.004.
   PubMed Web of Science ®Google Scholar
• Pierce BG, Hourai Y, Weng Z. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS One. 2011;6:e24657. doi:10.1371/journal.pone.0024657.
   PubMed Web of Science ®Google Scholar
• Shapovalov MV, Wang Q, Xu Q, Andrake M, Dunbrack RL Jr. BioAssemblyModeler (BAM): user-friendly homology modeling of protein homo- and heterooligomers. PLoS One. 2014;9:e98309. doi:10.1371/journal.pone.0098309.
   PubMed Web of Science ®Google Scholar
• Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 2013;41:W34–40. doi:10.1093/nar/gkt382.
   PubMed Web of Science ®Google Scholar
• Clark LA, Boriack-Sjodin PA, Eldredge J, Fitch C, Friedman B, Hanf KJ, Jarpe M, Liparoto SF, Li Y, Lugovskoy A, et al. Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci. 2006;15:949–60. doi:10.1110/ps.052030506.
   PubMed Web of Science ®Google Scholar
• Finlay WJ, Almagro JC. Natural and man-made V-gene repertoires for antibody discovery. Front Immunol. 2012;3:342. doi:10.3389/fimmu.2012.00198.
   PubMed Web of Science ®Google Scholar
• Almagro JC, Teplyakov A, Luo J, Sweet RW, Kodangattil S, Hernandez-Guzman F, Gilliland GL. Second antibody modeling assessment (AMA-II). Proteins. 2014;82:1553–62. doi:10.1002/prot.24567.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang Y, Liu Y, Wang Y, Jia H, Kang M, Luo X, Caballero D, Gonzalez J, Sherwood L, et al. Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists. Proc Natl Acad Sci U S A. 2015;112:1356–61. doi:10.1073/pnas.1423668112.
   PubMed Web of Science ®Google Scholar
• Nimrod G, Fischman S, Austin M, Herman A, Keyes F, Leiderman O, Hargreaves D, Strajbl M, Breed J, Klompus S, et al. Computational Design of Epitope-Specific Functional Antibodies. Cell Rep. 2018;25:2121–31 e5. doi:10.1016/j.celrep.2018.10.081.
   PubMed Web of Science ®Google Scholar
• Sormanni P, Aprile FA, Vendruscolo M. Third generation antibody discovery methods: in silico rational design. Chem Soc Rev. 2018;47:9137–57. doi:10.1039/c8cs00523k.
   PubMed Web of Science ®Google Scholar
• Zhao J, Nussinov R, Wu W-J, Ma B. In Silico Methods in Antibody Design. Antibodies. 2018;7(3):22.
   Web of Science ®Google Scholar
• Miller RA, Oseroff AR, Stratte PT, Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood. 1983;62:988–95.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2:256–65. doi:10.4161/mabs.2.3.11641.
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321:522–25. doi:10.1038/321522a0.
   PubMed Web of Science ®Google Scholar
• Lb A, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10:244–55. doi:10.1080/19420862.2017.1417718.
   PubMed Web of Science ®Google Scholar
• Finlay WJJ, Coleman JE, Edwards JS, Johnson KS. Anti-PD1 ‘SHR-1210ʹ aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement. MAbs. 2018;1–192019;11(1):26–44. doi:10.1080/19420862.2018
   Web of Science ®Google Scholar
• Ma D, Baruch D, Shu Y, Yuan K, Sun Z, Ma K, Hoang T, Fu W, Min L, Lan Z-S, et al. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol. 2012;12:88. doi:10.1186/1472-6750-12-88.
   PubMed Web of Science ®Google Scholar